| Literature DB >> 33013091 |
Gustav Strandvik1, Ayman El-Menyar2,3, Mohammad Asim2, Sagar Galwankar4, Hassan Al-Thani1.
Abstract
BACKGROUND: We aimed to assess the clinical characteristics, management practices, and inhospital outcomes of venous thromboembolism (VTE) among trauma patients.Entities:
Keywords: Outcomes; risk factors; trauma; venous thromboembolism
Year: 2020 PMID: 33013091 PMCID: PMC7472818 DOI: 10.4103/JETS.JETS_83_19
Source DB: PubMed Journal: J Emerg Trauma Shock ISSN: 0974-2700
Comparison of demographics and risk factors of trauma patients presented with deep-vein thrombosis versus pulmonary embolism
| Variables | Overall ( | DVT ( | PE ( | |
|---|---|---|---|---|
| Age, mean±SD | 46.2±18.8 | 44.4±17.1 | 50.0±21.7 | 0.20 |
| Males, | 46 (54.8) | 29 (51.8) | 17 (60.7) | 0.44 for all |
| Females, | 38 (45.2) | 27 (48.2) | 11 (39.3) | |
| Qatari, | 22 (26.2) | 14 (25.0) | 8 (28.6) | 0.72 |
| Body mass index, mean±SD | 30.6±7.4 | 31.6±8.0 | 28.3±5.2 | 0.09 |
| Locations of diagnosis, | ||||
| Inhospital wards | 34 (40.5) | 16 (28.6) | 18 (64.3) | 0.002 for all |
| Outpatient clinics | 50 (59.5) | 40 (71.4) | 10 (35.7) | |
| Risk factors, | ||||
| Lower-extremity fracture | 49 (58.3) | 29 (51.8) | 20 (71.4) | 0.08 |
| History of surgery (>24 h) | 30 (36.1) | 16 (28.6) | 14 (51.9) | 0.03 |
| History of DVT | 22 (26.5) | 14 (25.0) | 8 (29.6) | 0.65 |
| Pelvic fracture | 15 (17.9) | 8 (14.3) | 7 (25.0) | 0.22 |
| Bedridden | 12 (14.3) | 5 (8.9) | 7 (25.0) | 0.04 |
| Neck central line | 8 (9.6) | 3 (5.4) | 5 (18.5) | 0.05 |
| Paraplegia | 3 (3.6) | 2 (3.6) | 1 (3.6) | 1.00 |
| History of PE | 2 (2.4) | 0 (0.0) | 2 (7.4) | 0.03 |
| Femoral central line | 2 (2.4) | 1 (1.8) | 1 (3.7) | 0.59 |
| Surgery (within 24 h) | 1 (1.2) | 1 (1.8) | 0 (0.0) | 0.49 |
| Comorbidities, | ||||
| Obesity | 37 (52.9) | 29 (58.0) | 8 (40.0) | 0.17 |
| Hypertension | 21 (25.0) | 14 (25.0) | 7 (25.0) | 1.00 |
| Diabetes mellitus | 15 (17.9) | 8 (14.3) | 7 (25.0) | 0.22 |
| Hypercholesterolemia | 15 (17.9) | 9 (16.1) | 6 (21.4) | 0.54 |
| Hypertriglyceridemia | 8 (10.5) | 4 (7.1) | 4 (20.0) | 0.10 |
| Coronary artery disease | 5 (6.0) | 2 (3.6) | 3 (10.7) | 0.19 |
| Congestive heart failure | 2 (2.4) | 0 (0.0) | 2 (7.1) | 0.04 |
*Two patients initially presented with DVT developed PE on the follow-up. DVT: Deep-vein thrombosis, PE: Pulmonary embolism, SD: Standard deviation
Comparison of thrombophilic disorders and other laboratory findings
| Overall ( | DVT ( | PE ( | ||
|---|---|---|---|---|
| Thrombophilic disorders, | ||||
| Hyperhomocysteinemia | 6 (7.1) | 4 (7.1) | 2 (7.1) | 1.00 |
| Protein C deficiency | 7 (8.3) | 3 (5.4) | 4 (14.3) | 0.16 |
| Protein S deficiency | 5 (6.0) | 1 (1.8) | 4 (14.3) | 0.02 |
| Antithrombin III deficiency | 4 (4.8) | 1 (1.8) | 3 (10.7) | 0.07 |
| Factor V leiden | 2 (2.4) | 2 (3.6) | 0 (0.0) | 0.31 |
| Antiphospholipid syndrome | 1 (1.2) | 1 (1.8) | 0 (0.0) | 0.47 |
| Lupus anticoagulation | 4 (4.8) | 3 (5.4) | 1 (3.6) | 0.71 |
| SVC/IVC thrombosis | 1 (1.2) | 1 (1.8) | 0 (0.0) | 0.47 |
| D-dimer ( | ||||
| Positive (>0.55 mg/L), | 54 (90.0) | 37 (88.1) | 17 (94.4) | 0.45 for all |
| Negative, | 6 (10.0) | 5 (11.9) | 1 (5.6) | |
| D-Dimer (mg/L FEU), median | 8.4 (0.2-1470) | 11.4 (0.2-1470) | 5.6 (0.3-36.1) | 0.30 |
| Echocardiography, | 35 (41.7) | 20 (35.7) | 15 (53.6) | 0.11 |
| Ejection fraction (%), mean±SD | 54.6±8.4 | 55.7±6.6 | 53.2±10.4 | 0.39 |
| RV wall hypokinesis, | 3 (8.1) | 2 (10.0) | 1 (5.9) | 0.64 |
| Pulmonary arteries dilation, | 5 (13.5) | 4 (20.0) | 1 (5.9) | 0.21 |
| Routine laboratory, mean±SD | ||||
| WBC count | 10.1±4.9 | 9.7±4.2 | 10.9±6.1 | 0.28 |
| Hemoglobin | 12.3±2.3 | 12.7±2.2 | 11.4±2.3 | 0.01 |
| Platelet count | 300±177 | 268±97.4 | 363±266 | 0.02 |
| Hematocrit | 36.9±7.4 | 38.3±6.5 | 34.1±8.3 | 0.01 |
SVC/IVC: Superior vena cava/inferior vena cava, DVT: Deep-vein thrombosis, PE: Pulmonary embolism, RV: Right ventricular, WBC: White blood cell, SD: Standard deviation
Management and outcome of trauma patients presented with deep-vein thrombosis versus pulmonary embolism
| Overall ( | DVT ( | PE ( | ||
|---|---|---|---|---|
| Treatment | ||||
| Warfarin | 66 (78.6) | 45 (80.4) | 21 (75.0) | 0.57 |
| Enoxaparin | 64 (76.2) | 45 (80.4) | 19 (67.9) | 0.20 |
| Dalteparin | 33 (39.3) | 18 (32.1) | 15 (53.6) | 0.05 |
| Heparin | 19 (22.6) | 6 (10.7) | 13 (46.4) | 0.001 |
| Aspirin | 26 (31.0) | 17 (30.4) | 9 (32.1) | 0.86 |
| Plavix | 8 (9.5) | 6 (10.7) | 2 (7.1) | 0.59 |
| Thrombolytic therapy | 4 (4.8) | 2 (3.6) | 2 (7.1) | 0.46 |
| Warfarin treatment for <2 years | 49 (58.3) | 32 (57.1) | 17 (60.7) | 0.75 |
| Warfarin for life | 10 (11.9) | 9 (16.1) | 1 (3.6) | 0.09 |
| Hospital length of stay (days) | 7.5 (1-270) | 7 (2-270) | 14 (1-240) | 0.15 |
| Postthrombotic syndrome | ||||
| Calf pain | 62 (73.8) | 48 (85.7) | 14 (50.0) | 0.001 |
| Leg edema | 49 (58.3) | 37 (66.1) | 12 (42.9) | 0.04 |
| Leg ulcer | 4 (4.8) | 4 (7.1) | 0 (0.0) | 0.14 |
| Mortality | 7 (8.3) | 5 (8.9) | 2 (7.1) | 0.78 |
DVT: Deep-vein thrombosis, PE: Pulmonary embolism